Drug Profile
Anti-GPC3 chimeric antigen receptor T cell therapy - Shanghai Genechem
Alternative Names: Anti-GPC3 CAR-T - Shanghai Genechem; GPC3-CART cells; TAI-GPC3-CART cells - Shanghai GenechemLatest Information Update: 22 Oct 2020
Price :
$50
*
At a glance
- Originator Shanghai Genechem
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 22 Oct 2020 No development reported - Phase-I/II for Liver cancer (Late-stage disease, Second-line therapy or greater) in China (Infusion)
- 22 Oct 2020 No development reported - Phase-I/II for Liver cancer (Late-stage disease, Second-line therapy or greater) in China (Intratumoural)
- 01 Apr 2017 Phase-I/II clinical trials in liver cancer (Late-stage disease, Second-line therapy or greater) in China (Intratumoural) (NCT03130712)